PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials
Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP)
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these
Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation
Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially
Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical
https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4
The 1st ILEP Symposium has come to an end. Finally, we are ready to share the official statistics of this event. Please see the attached
We are pleased to invite you to participate in a free webinar organized by the European Atherosclerosis Society (EAS) together with The Polish Lipid Association,
Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing
ILEP strongly believes in international cooperation and the power of diversity, which is why representatives of many nationalities are an essential part of our community. If you are interested in becoming part of ILEP, we invite you to complete the contact form below. Our team will be happy to provide you with more information and guide you through the next steps.
In 2025 we have been able to publish >10 papers, in which many of the ILEP members were included:
ILEP Executive Committee Meeting
Publication of ILEP meta-analysis on the role of PCSK9/ANGPTL3 inhibitors in HoFH Patients
Presentation of NEW ILEP Consensus Statements on ischemic stroke prevention at the ESC EuroStroke & EuroThrombosis in Milan with simultaneous publication in PSCVD
Presentation of the Assumption of the European Program for Prevention (EPP) with the publication on this in the Global Heart by the WHF (Nov. 2025)
10th Anniversary Congress of the International Lipid Expert Panel in Warsaw
ILEP Webinars Recommendations 2021
The 2nd Edition of ILEP Webinars starts.
ILEP hosts the 1st Edition of ILEP Webinars.
Professor Maciej Banach founds the International Lipid Expert Panel.
